New Enterprise Associates related stories
All articles and analysis
Shire acquires VC-backed Lumena PharmaceuticalsShire has acquired Lumena Pharmaceuticals. No financial terms were disclosed. Citi provided financial advice to Lumena. Based in San Diego, Lumena is a biopharmaceutical company focused on rare cholestatic liver diseases and serious metabolic disorders. Its backers include New Enterprise Associates, Adage Capital Management, RA Capital Management, Pappas Ventures, RiverVest Venture Partners and Alta Partners.
- Pinnacle Engines bags Series C funds
Pinnacle Engines has closed its Series C funding, bringing the total investment in the firm to more than $30 million. Investors included Mitsui Global Investment, VenturEast, Bessemer Venture Partners, New Enterprise Associates and Infield Capital. Also, the firm has named Phil Murtaugh, John Parker, BVR Subbu, Hong Liang Lu and Freeman Shen to its newly formed Asian business advisory board. Headquartered in Silicon Valley, Pinnacle Engines is a maker of "ultra-efficient" engine designs.
- Igneous Systems garners $23.6 mln Series A funds
Igneous Systems said Wednesday that it raised $23.6 million in Series A financing. New Enterprise Associates led the round with participation from Madrona Venture Group, Redpoint Ventures and Isilon Systems co-founder, Sujal Patel. According to the firm, the capital will be used for product development and to expand its engineering and leadership teams. Concurrent with the funding, Ron Bernal, venture partner at NEA, has been added to Igneous Systems' board of directors. Based in Seattle, Igneous System is "reimagining the future of rapidly-expanding data center infrastructures."
- NEA leads Series B round for Loxo Oncology
Loxo Oncology has received $24 million in Series B financing. New Enterprise Associates led the round with participation from previous backers Aisling Capital and OrbiMed Advisors. In addition to the funding, Dr. M. James Barrett, a general partner at NEA, will join Loxo Oncology's board of directors while Dr. Sara Nayeem, a principal at NEA, will also join the board as an observer. And, the firm has named Dr. Mikel Moyer as chief scientific officer. Loxo Oncology is a a biopharmaceutical company focused on targeted cancer therapies.
- IPO Profile: Trivascular Inc
Delphi Ventures, Kearny Venture Partners, MPM Capital and New Enterprise Associates as a group own 8.7 million shares worth about $105 million at the IPO price.
IPO Profile: Opower IncAccel Partners, Kleiner Perkins, MHS Capital and New Enterprise Associates as a group own 16.9 million shares worth more than $320 million at the IPO price. NEA is the largest shareholder, with holdings worth about $171 million.
- ZeroFOX grabs $10.7 mln in round led by NEA
ZeroFOX said Wednesday that it has raised $10.7 million in Series A funding. New Enterprise Associates led the round with participation from Genacast Ventures, Core Capital and the State of Maryland. Based in Baltimore, ZeroFOX is a provider of solutions that combat social cyber attacks.
- Golub Capital supports NEA and Frazier's dividend recap of DSI Renal
Golub Capital said Friday that it helped provide a $400 million credit facility to support Frazier Healthcare and New Enterprise Associates' dividend recap of DSI Renal. Headquartered in Nashville, DSI is a provider of dialysis services in the U.S.
- NEA leads Series A round for APX Labs
APX Labs said Tuesday that it has closed $10 million in Series A funding. New Enteprise Associates led the round. In addition to the funding, Peter Barris and Dayna Grayson of NEA will join the firm's board of directors. Headquartered in Herndon, Virginia, APX Labs is a maker of an enterprise smart glasses platform.
- CIT GAP Funds backs children's literacy startup Zoobean
CIT GAP Funds has made an undisclosed investment in Zoobean. Based in Arlington, Zoobean creates personalized selections of children's apps, books and reading guides.